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Abstract: Toxins are potent molecules used by various bacteria to interact with a host 
organism. Some of them specifically act on neuronal cells (clostridial neurotoxins) leading 
to characteristics neurological affections. But many other toxins are multifunctional and 
recognize a wider range of cell types including neuronal cells. Various enterotoxins 
interact with the enteric nervous system, for example by stimulating afferent neurons or 
inducing neurotransmitter release from enterochromaffin cells which result either in 
vomiting, in amplification of the diarrhea, or in intestinal inflammation process. Other 
toxins can pass the blood brain barrier and directly act on specific neurons. 
Keywords:  toxin; neurotoxin; enterotoxin; nervous system; actin cytoskeleton; small 
gtpases; neurotransmitter 
 
1. Introduction 
Pathogenic bacteria use various strategies to interact with target tissues and cells of the host organism. 
Among them, toxin production constitutes an efficient way to alter specific functions of target cells. 
Toxins can act locally or at a distance from the infectious site and are responsible for severe diseases in 
man and animals. While some toxins, called cytotoxins, cause disruption of all cell types, thus permitting 
the pathogen access to nutrients, other toxins are only active on specific cells such as enterotoxins active 
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on epithelial intestinal cells and neurotoxins targeting neuronal cells. This is achieved by the recognition 
of specific cell surface receptor(s) and/or specific intracellular target(s). When bound to the receptor, 
toxins can unleash their toxic program at the cell membrane by interfering with signal transduction 
pathways, pore formation, or enzymatic activities towards membrane compounds. In contrast, other 
toxins enter the cytosol, recognize, and modify specific intracellular targets. According to the nature of 
the target and the type of modification, intracellular active toxins cause a dramatic alteration of cellular 
functions such as protein synthesis, cell homeostasis, cell cycle progression, vesicular traffic, and actin 
cytoskeletal rearrangements. The nervous system which is diffused through all the organism is one of the 
main target of bacterial toxins. If neurotoxins, like clostridial neurotoxins, exclusively interact with 
neuronal cells from the central or peripheral nervous system inducing specific neurological symptoms, 
other toxins recognize a broader range of cell types including neuronal cells. For example, cytotoxins 
can trigger necrosis or apoptosis in various cell types as well as in neuronal cells. Thereby various toxins, 
in addition to their specific activity on some cell types, affect certain neuronal cells, directly or indirectly, 
leading to neurological symptoms associated with typical clinical signs resulting from the other affected 
cells (Table 1, and Figure 1). This review is focused on the various modes of interaction with neuronal 
cells of bacterial neurotoxins and other toxins affecting the nervous system. 
2. The Cellular and Molecular Mechanisms Involved in Neuroexocytosis: An Overview 
2.1. An overview of neurotransmission 
Transfer of information or command between neurons, or neurons and target cells (muscle fibers, 
endocrine cells, etc.) is most often chemical in nature and occurs at highly specialized contact sites 
termed synapses. Here, the release of neurotransmitter molecules by the presynaptic elements enables 
activation of receptors localized on the postsynaptic target. Neurotransmitter molecules are comprised 
of small organic molecules as acetylcholine (ACh), catecholamines like dopamine or noradrenaline, 
serotonin (5-HT), glutamate, gamma-aminobutyric acid (GABA), glycine, adenosine-triphosphate 
(ATP), and numerous peptides such as vaso-intestinal peptide (VIP), substance P (SP), and calcitonin 
gene-related protein (CGRP). Released transmitter substance(s) can activate ligand-gated ionic 
channels or metabotropic receptors, thus mediating either transmembrane ionic fluxes or activation of 
intracellular signaling pathway(s). For example, in the central nervous system, depending on the ion 
species flowing through the channel, activation of ligand-gated ionic channels can cause depolarization 
(i.e., excitation) or hyperpolarization (i.e., inhibition) of the postsynaptic plasma membrane, 
respectively, and the excitation/inhibition net balance determines eventual initiation of action 
potentials propagated in the neuron until the next synapses. The evoked endplate potential at muscle 
fibers following stimulation of the motor nerve (and subsequent ACh release) is a depolarization that 
may reach the threshold for initiating muscle action potential, which itself propagates along muscle 
fiber ultimately triggering its contraction. In the enteric nervous system, release of neurotransmitter 
molecules (as VIP) by mucosal nerve endings directly contacting the enterocytes, or indirectly via the 
activation of entero-chrommaffin cells releasing 5-HT, can lead to activation of metabotropic 
receptors, intracellular activation of the adenylate cyclase and downstream cAMP-dependent 
pathways, resulting in an active co-transport of ions species (Na
+, K
+, Cl
−) and water efflux for 
osmotic compensation in the intestine lumen (viz the molecular mechanisms of diarrhoea [5]).  Toxins 2010, 2                 
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Table 1. Bacterial neurotoxins and other toxins interacting with the nervous system. 
Toxin Bacteria  Structure  Target neuronal 
cell  Receptor Activity  Effects 
MLD 
(μg/kg)
1 
Toxins inhibiting the neuroexocytosis 
Botulinum 
neurotoxins 
C. botulinum 
C. baratii 
C. butyricum 
single chain protein 
(150 kDa)  motoneurons 
gangliosides 
(GD1b, GT1b) 
synaptotagmin, 
SV2 
proteolysis of 
SNARE proteins 
(VAMP, 
SNAP25, 
syntaxin) 
inhibiton of 
acetylcholine 
release (flaccid 
paralysis) 
0.0003 
Tetanus 
neurotoxin  C. tetani  single chain protein 
(150 kDa) 
inhibitory 
interneurons 
gangliosides 
(GD1b, GT1b) 
GPI-anchored 
protein 
proteolysis of 
SNARE protein 
(VAMP) 
inhibition of 
neurotransmitter 
release (GABA, 
glycine) (spastic 
paralysis) 
0.001 
Lethal toxin  C. sordellii  single chain protein 
(250 kDa) 
potentially all 
neurons  unknown 
inactivation of 
Rho and Ras-
GTPases 
(glucosylation) 
inhibition of 
neurotransmitter 
release 
0.1 
Toxin B  C. difficile  single chain protein 
(250 kDa) 
potentially all 
neurons  unknown 
inactivation of 
Rho-GTPases 
(glucosylation) 
inhibition of 
neurotransmitter 
release 
32 
Pneumolysin  S. pneumoniae  single chain protein 
(53 kDa) 
hippocampal 
neurons  cholesterol  pore-forming 
activity 
neuronal 
apoptosis 
(meningitis) 
 
Enterotoxin  C. perfringens  single chain protein 
(36 kDa) 
enterocyte 
neurons    pore-forming 
activity   80 
Toxins stimulating neurosecretion 
Epsilon toxin  C. perfringens  single chain protein 
(36 kDa) 
hippocampal 
neurons  unknown  pore-forming 
activity 
stimulation of 
glutamate 
release 
(excitation) 
0.1 Toxins 2010, 2                 
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Table 1. Cont. 
Cholera toxin  V. cholerae  AB5 structure 
enterochrompaffin 
cells and enteric 
neurons 
ganglioside GM1 
inactivation of 
Gsα and 
activation of 
adenylate cyclase
5-HT release 
(diarrhea) 
250 
Heat labile 
enterotoxin 
E. coli  AB5 structure 
enterochromaffin 
cells and enteric 
neurons 
ganglioside GM1 
inactivation of 
Gsα and 
activation of 
adenylate cyclase
5-HT release 
(diarrhea) 
250 
Toxin A  C. difficile 
single chain protein 
(300 kDa) 
enterocytes 
enteric neurons 
membrane 
glycoprotein 
inactivation of 
Rho-GTPases, 
other 
mechanism? 
release of 
inflammatory 
mediators and 
neuropeptides 
(diarrhea) 
0.35 
Heat stable 
enterotoxin 
E. coli 
short peptide 
(2–5 kDa) 
enterocyte 
enteric neurons? 
guanylate cyclase 
GMPc increase, 
other 
mechanism? 
stimulation of 
enteric nervous 
system 
(diarrhea) 
 
Staphylococcal 
enterotoxins 
S. aureus 
single chain protein 
(25–30 kDa) 
enterochromaffin 
cells, vagal nerve 
histocompatibility 
complex class II 
molecules 
superantigen 
other 
mechanism? 
5-HT release 
stimulation of 
5-HT3 receptor 
(emesis) 
20 
(monkey) 
Cereulide  B. cereus 
cyclic 
dodecadepsipeptide 
(1.2 kDa) 
vagal nerve  5HT3 receptor  K
+ ionophore 
stimulation of 
5-HT3 receptor 
(emesis) 
 
1 Mouse lethal doses per kg of body weight according to [1–4]. 
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Figure 1. Schematic representation of bacterial toxins active on the nervous system. 
 
In nerve terminals, transmitter molecules are stored into at least two different classes of secretory 
organelles: the small lucent synaptic vesicles, and large dense core vesicles or granules. The small 
lucent vesicles, approximately 50 nm in diameter, contain small organic molecules and are formed by 
either budding from the early endosome or recycling of empty vesicles [6,7]. The large dense core Toxins 2010, 2                 
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vesicles are analogous to the secretory granules present in endocrine and exocrine cells and have a 
biogenesis different from that of the synaptic vesicles. Similar to many cargo vesicles, they are formed 
by vesicle budding from the trans-Golgi system, followed by homotypic fusion to form larger vesicles. 
Usually they mediate release of peptide transmitter or certain catecholamines whose synthesis depends 
on the presence in the granule lumen of enzymes (as the dopamine-beta-hydroxylase). Small synaptic 
vesicles and certain large dense core vesicles are equipped with a vacuolar-type ATPase that creates a 
proton gradient which drives specific vesicular transporters, thereby allowing active uptake and 
storage of neurotransmitter molecules inside these vesicles. Regardless the secretory organelle size, 
large or small, the release of its content into the extracellular space implicates a fusion of its membrane 
with the plasmalemma, which then allows passive diffusion of its content into the surrounding 
medium. This exocytotic process is triggered by a rise in the cytosolic concentration of Ca
++, in 
response either to the arrival of a propagated action potential (i.e., at the neuron nerve endings) or 
following activation of ionotropic or/and metabotropic receptors located on the plasma membrane of 
secretory cells [8]. 
2.2. Mechanisms of exocytosis and SNAREs 
More than 100 proteins are implicated in Ca
++-dependent exocytosis. However, only a dozen of 
them participate in the core machinery required for transmitter release, while the others serve 
regulatory roles  [9,10]. Interestingly, several proteins of the release machinery are targeted and 
disabled by various bacterial toxins. A large body of evidence indicates that the synaptic vesicles do 
not move freely within the nerve ending cytosol, and regulation of their interaction with actin-based 
cytoskeleton allows fine tuning of their movements  [11,12]. At the fusion site, they bind to the 
scaffold proteins associated with a special presynaptic matrix termed “active zone”  [12]. When 
tethered to the fusion site, the synaptic vesicles are not yet fusogenic and must acquire fusion 
competence. A key step in this process is the pairing and assembly of a fusion particle comprised of 
VAMP (vesicle-associated membrane protein, also termed synaptobrevin), SNAP-25, and syntaxin, on 
the inner face of the plasma membrane (reviewed by [9,10]). These three proteins are also designed as 
the SNARE proteins (soluble  N-ethylmaleimide-sensitive factor attachment protein receptors).  
Munc-18 protein is the fourth essential protein partner, it participates in SNARE complexe formation 
and binds to it (reviewed by [9,10]).The SNARE proteins or closely related isoforms are also involved 
in the fusion of large dense core vesicle or secretory granules. Assembly of the three SNAREs, and 
possibly munc-18, triggers hemifusion of vesicles and plasma membrane. Termination of fusion is 
triggered by a rise in intracellular Ca
++ concentration, which may result from either Ca
++ influx 
through voltage-gated channels (e.g., at nerve terminals), Ca
++ release from intracellular stores, or both 
(e.g., at many neuroendocrine cells)  [13,14]. The principal Ca
++  sensor for triggering fusion is 
synaptotagmin, which is an integral synaptic vesicle protein interacting with SNAREs [10,15–17]. 
Synaptotagmin is equipped with two “C2-domains”, which acquire high affinity for membrane lipids 
upon binding to Ca
++ ions but in a pretty high intracellular concentration (10–100 µM). Thus 
synaptotagmin is likely sensing the Ca
++ changes due to activation of voltage-dependent calcium 
channels. Its Ca
++-dependent interaction with plasma membrane leads to changes in membrane 
curvature and destabilization of the lipids permitting the fusion [18]. Several SNARE/synaptotagmin 
complexes (possibly 4 to 6) must act synergistically to allow fusion of a synaptic vesicle (reviewed Toxins 2010, 2                 
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by [9,10]). Recently, a role similar to that of synaptotagmin has been assigned to the Doc2 protein, 
given the high affinity of Doc2 for Ca
++. Thus, Doc2 is likely intervening in spontaneous exocytosis at 
nerve endings and secretory cells, which is triggered/regulated by minute changes in the resting 
intracellular Ca
++ concentration [19]. 
2.3. Actin cytoskeleton and small GTPases in exocytotic mechanisms 
Many other proteins play key roles in synaptic vesicle trafficking and priming of tethered synaptic 
vesicles. Inside nerve terminals, vesicles traffic along actin filaments and this implicates molecular 
motors like myosins II or V, and small GTPases of the Rab family (Rab3 and others)  [20,21]. 
Reorganization of the actin cytoskeleton is coupled to Ca
++-regulated exocytosis in endocrine cells. 
However, this is far from being clear in neurons [11,22,23]. The role of actin in exocytosis seems to 
consist in governing the vesicle-granule trafficking towards release site [22,23]. Organization of the 
actin-based cytoskeleton is controlled by several proteins, including several small GTPases like Rho 
proteins [24] and ADPribosylation factor (ARF). Like most small GTPases, ARF and Rho proteins 
cycle between GDP-bound (inactive), and GTP-bound (active) states, thereby acting as signal 
transducers that respond to upstream signals. Thus, they activate downstream effector molecules which 
carry out their biological functions. Rho proteins (Rho, Rac, Cdc42) are widely-expressed monomeric 
GTPases. Their translocation to specific membrane domains enables intervention of distinct biological 
functions, including: (1) regulation of actin cytoskeletal dynamics; (2) cell cycle progression; (3) gene 
transcription; (4) membrane transport; and 5) exo-/endo-cytosis [23,24]. In chromaffin and PC12 cells, 
RhoA associates with secretory granules, whereas Rac1 and Cdc42 are found in the subplasmalemmal 
region  [23]. Activation of phosphatidylinositol 4-kinase by RhoA promotes the formation of   
granule-associated actin filaments and/or stabilize the subplasmalemmal actin barrier [23]. In 
chromaffin cells, Cdc42 and Rac1 control actin polymerization and secretion [25,26]. In neurons, Rac1 
is associated with synaptic vesicles and plasma membrane [27]. Rac1 is involved in a post-docking 
step of neuronal exocytosis during which it controls in an all-or-none manner the functionality of 
release sites  [27,28], possibly via regulation of phospholipase D (PLD) activity  [29]. Additional 
pathways converging on PLD1 implicates ARF6 GTPases  [30]. Ral-GTPase is abundant in nerve 
terminals and associates with synaptic vesicles [31]. This molecule apparently plays a key role in 
neurotransmitter release by regulating the pool size of readily releasable synaptic vesicles [32]. Ral has 
been implicated in regulating PLD activity too [33]. Downstream from ARF6, Ral, Rho, Rac, and 
Cdc42, PLD produces PA. PLD is possibly activated by these GTPases upon docking of synaptic 
vesicles, or secretory granules, at the release sites. PLD activation is an important event for exocytosis 
in neurons and many secretory cell types [34–37]. PLD-production of phosphatidic acid (PA) may 
either signal attachment of some proteins of the fusion machinery to the fusion site or play a role in 
vesicle fusion. Indeed, PA is a cone-shaped lipid whose local accumulation, and possibly 
destabilization of the lipids at the fusion site [35–37] may promote negative curvation of the inner 
(cytoplasmic) plasma membrane leaflet [38]. 
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3. Toxins Inhibiting the Neuroexocytosis 
3.1. Toxins which specifically impair the SNARE exocytosis mechanism: Clostridial neurotoxins 
Clostridium  botulinum and Clostridium  tetani secrete very potent neurotoxins, which are 
responsible for neurological disorders in humans and animals, botulism and tetanus, respectively. 
Several recent reviews detail the structure and mode of action of neurotoxins [39–45]. 
C. tetani forms a homogeneous bacterial species which produces only one type of tetanus toxin (TeNT), 
whereas botulinum neurotoxin (BoNT)-producing strains are heterogeneous. C. botulinum is divided 
into 4 groups, which on the basis of phenotypic and genotypic parameters, correspond to different 
species. In addition, some strains of other species, such as Clostridium butyricum and Clostridium 
baratii, can produce a related BoNT type E and F, respectively. Seven BoNT toxinotypes (A, B, C, D, 
E, F, and G) are distinguished according to their antigenic properties. Each toxinotype is now divided 
into subtypes based on BoNT sequence variations, which can impact antibody binding and 
neutralization or affinity as well as catalytic efficiency for their substrate [46–51]. 
BoNTs are associated with non-toxic proteins (ANTPs) to form large complexes. ANTPs 
encompass a non-toxic and non-hemagglutinin component (NTNH) and several hemagglutinin 
components (HA34, HA17 and HA70 in C. botulinum A) or OrfX components [44,52]. Recent model 
and composition of BoNT complexes have been proposed [53,54]. The function of ANTPs is still 
unclear; they could protect the neurotoxin from the acidic pH of the stomach and from   
digestive proteases. 
3.1.1. Structure 
BoNTs and TeNT share a common structure. They are synthesized as a precursor protein (about 
150 kDa), which is inactive or weakly active. The precursor which does not contain signal peptide, is 
released from the bacteria possibly by a yet misunderstood cell-wall exfoliation mechanism [55]. The 
precursor is proteolytically activated in the extra-bacterial medium either by Clostridium proteases or 
by exogenous proteases such as digestive proteases in the intestinal content. The active neurotoxin 
consists of a light chain (L, about 50 kDa) and a heavy chain (H, about 100 kDa), which remain linked 
by a disulfide bridge. The structure of BoNTs shows three distinct domains: L-chain containing  
α-helices and β-strands and including the catalytic zinc binding motif, the N-terminal part of the  
H-chain forming two unusually long and twisted α-helices, and the C-terminal part of the H-chain 
consisting of two distinct subdomains (HCN and HCC) involved in the recognition of the receptor. 
While the three domains are arranged in a linear manner in BoNT/A and BoNT/B, both the catalytic 
domain and the binding domain are on the same side of the translocation domain in BoNT/E. This 
domain organization in BoNT/E might facilitate a rapid translocation process [56–65]. 
The overall sequence identity at the amino acid level beween BoNTs and TeNT ranges from 34 to 
97%. Several domains are highly conserved which account for the common mode of action of these 
toxins. Thereby, the central domains of L chains are related in all the clostridial neurotoxins and 
contain the consensus sequence (His-Glu-X-X-His) characteristic of zinc-metalloprotease active site. 
The half N-terminal domain of the H-chains is also highly conserved, and it is involved in the 
translocation of the L-chain into the cytosol. Thus, a similar mechanism of internalization of the Toxins 2010, 2                 
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intracellular active domain into target cells is shared by all the clostridial neurotoxins. In contrast, the 
half C-terminal parts of H-chain, mainly the HCC subdomains, are the most divergent [44,52]. This 
accounts for the different receptors recognized by the clostridial neurotoxins (see below). 
3.1.2. Mode of action 
Although BoNTs and TeNT use different routes, they display a similar intracellular mechanism of 
action. BoNTs enter by oral route or are produced directly in the intestine subsequently to a  
C. botulinum intestinal colonization and then undergo a transcytosis across the digestive mucosa   
[66–71]. After diffusion into the extracellular fluid and blood stream circulation, BoNTs target 
motoneuron endings. In contrast, TeNT is formed in wounds colonized by C. tetani. TeNT diffuses in 
the extracellular fluid and can target all types of nervous endings (sensory, adrenergic neurons and 
motoneurons), but it is mainly retrogradelly transported through the motoneurons (see below) [72–74]. 
Each type of BoNT and TeNT recognizes specific receptors on demyelinated terminal nerve 
endings, mainly through the HCC subdomain. BoNT/A, /C, /E, /F exploit the three isoforms of the 
vesicle protein SV2 as specific receptors, while BoNT/B and /G bind to synaptotagmin I or II [75–81]. 
The GPI-anchored membrane protein Thy-1 has been proposed to act as a TeNT receptor [82,83], but 
this has not been confirmed. Ganglioside-binding sites have been characterized in the HCC subdomain. 
Interestingly, TeNT exhibits two carbohydrate-binding sites, whereas BoNT/A and BoNT/B show 
only one [63,84–86]. Accordingly, TeNT can bind simultaneously to two gangliosides [87]. BoNT/C 
and BoNT/D interact with gangliosides (GD1b, GT1b) and phosphatidylethanolamine, respectively by 
their HCC subdomain [88]. The role of HCN subdomain, which may interact with phosphatidylinositol 
phosphates [89], is still unclear. Overall, whatever the considered clostridial neurotoxin, the identified 
protein receptors are not neurospecific and are expressed on several cell types including intestinal 
crypt epithelial cells in the intestine [69]. Distribution of the gangliosides recognized by BoNTs differs 
from that of the protein receptors. Thus, the high affinity of BoNTs and TeNT for presynaptic 
membranes probably results from multiple and synergistic interactions with the ganglioside and 
protein parts of receptor, and binding to gangliosides which induces conformational changes in the Hc 
domain, probably facilitates subsequent binding to protein receptor [90,91]. Co-presence of the ad hoc 
ganglioside(s) and protein receptors likely facilitates the identification of cell subset targeted by TeNT 
or BoNTs at very low concentrations encountered in the physiological medium during the disease. At 
higher concentrations, binding to the protein receptor is likely sufficient for mediating toxin binding. 
Indeed the number of cell types affected by these toxins expands with increasing toxin concentrations. 
Therefore, BoNTs can target numerous neurons but not all, as well as non-neuronal cells at high 
concentrations, inhibiting the release of various compounds (Table 2). 
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Table 2. Clostridial neurotoxins block the release of many different neurotransmitters and other molecules in neuronal and in some  
non-neuronal cells. However, the release of certain neurotransmitters is resistant to BoNTs, either the target cells do not express the specific 
receptor(s) for BoNT entry or the intracellular target (SNARE protein) do not contain BoNT cleavage site. 
Neurotransmitter Model  system  References 
Blockage of neurotransmitter and other molecule release by BoNTs in neuronal cells 
Acetylcholine (ACh)  Skeletal muscular junction 
Torpedo electric organ 
Aplysia, CNS 
 [92] 
 [93] 
 [94] 
Glutamate Brain  synaptosome 
Hind paw/mass spectrometry 
Cultured rat cerebellar neurons/radioassay 
Cultured rat cerebellar neurons/enzymatic assay
 [95] 
 [96] 
 [97] 
 [98] 
Aspartate  Brain synaptosomes   [99] 
Gamma aminobutyric acid (GABA)  Brain synaptosomes   [99,100] 
Glycine Spinal  cord  neurons (culture)   [101] 
Dopamine 
Adrenalin 
Noradrenalin 
Brain synaptosomes   [100,102] 
Serotonin (or 5-HT)  Brain synaptosomes   [103] 
ATP corelease with ACh  Torpedo synaptosomes 
Rat bladder urothelium 
Guinea pig stellate neurons 
 [104] 
 [105,106] 
 [107] 
Nicotinamide adenine dinucleotide (NAD)  Canine mesenteric artery 
Human urinary bladder detrusor muscle 
 [108] 
 [109] 
Effects on other neuropeptides 
Substance P (SP)  Inhibition of KCl evoked SP release   Toxins 2010, 2                 
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Table 2. Cont. 
Calcitonin gene-related peptide 
(CGRP) 
Inhibition of release in cultured dorsal root ganglia (DRG) neurons 
Inhibition of release in cultured rat bigeninal nerve cells 
Rat bladder afferent neurons 
Upregulation and increase of CGRP 
 [110,111] 
 [112] 
 [113] 
 [114–117] 
Neurotransmitter release resistant to BoNTs 
Vaso intestinal peptide (VIP), 
CGRP 
Periglandular innervation of sweat glands   [118] 
Neuropeptide Y  Vasoconstrictor neurons afferent to vena cava and uterine artery from guinea pig   [119] 
SP  Capsain evoked release from cultured DRG   [110] 
Nitric oxide (NO) 
ACh 
Non vesicular fraction of 5-HT evoked ACh release at bronchiolar smooth muscle 
(ACh release by epithelial cells ?) 
 [119–121] 
GABA  Cultured inhibitory hippocampal interneurons (BoNT-resistant SNAP25 related 
isoform ?) 
 [122] 
Blockage of the process release in non-neuronal cells by BoNTs at high concentrations (≥100 nM) 
Catecholamines  Chromaffin cells   [123–125] 
ATP, glutamate  Glial cells: astrocytes or Schwann cells   [126–128] 
Insulin Pancreatic  beta-cells   [129] 
Store-mediated Ca
++ entry  Exocrine pancreas cells   [130] 
Store-mediated Ca
++ entry  Platelets   [131] 
Blockage of neurotransmitter by TeNT 
Glycine  Cat, rat spinal cord 
Murine spinal cord cell cultures (complete blockage of evoked and spontaneous 
release) 
 [132,133] 
 [134] 
 
GABA Rat  brain 
Pig cerebrocortical synaptosomes 
Rat hippocampal slices 
Cerebellar cell cultures 
 [135] 
 [99] 
 [136–138] 
 [139] Toxins 2010, 2                 
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Table 2. Cont. 
Glutamate  Murine spinal cord cell cultures (partial blockage of evoked release and 
increase in spontaneous release) 
Rat brain 
Cerebellar neuronal cells 
Pig cerebrocortical synaptosomes 
Cultured hippocampal neurons (blockage of AMPA receptor insertion 
via SNARE-dependent exocytosis) 
Synaptosomes 
 [134] 
 
 [140] 
 [141] 
 [99,142] 
 [143,144] 
 [142] 
Aspartate  Pig cerebrocortical synaptosomes 
Brain synaptosomes 
Brain slices 
Synaptosomes (no inhibition of evoked aspartate release) 
 [99] 
 [138] 
 [145] 
 [142] 
Catecholamines  Cultured brain neurons 
Chromaffin cells 
Synaptosomes 
Rat brain 
 [146] 
 [147–151] 
 [152,153] 
Serotonin Rat  brain 
Synaptosomes 
Synaqptosomes (inhibition of serotonin uptake) 
 [152,153] 
 [154] 
 [155–158] 
Acetylcholine  Chromaffin PC12 cells 
Synaptosomes 
Aplysia californica neurons (intraneural injection) 
 [159,160] 
 [161,162] 
 [163] 
Met-enkephalin Pig  cerebrocortical synaptosomes   [99] 
Blockage of exocytosis in non neuronal cells by TeNT 
Glutamate Astrocytes    [164] 
Transferrin receptor  CHO cell (cleavage of cellubrevin)   [165] 
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Neurotoxin bound to its receptor is internalized by receptor-mediated endocytosis. An essential 
difference between both types of neurotoxins is that BoNTs are directly endocytosed in clathrin-coated 
vesicles, which, when acidified, trigger the translocation of the L chain into the cytosol. Therefore, 
BoNT L chain is delivered in the peripheral nervous system, to neuromuscular junctions where it 
blocks the release of acetylcholine leading to a flaccid paralysis. In contrast, TeNT enters different 
endocytic vesicles, which are not acidified. The vesicles retrogradely transport the toxin in a 
microtubule-dependent manner to the cell body of neurons in the spinal cord. Like nerve growth 
factors, TeNT is transported by tubulo-vesicular organelles characterized by the presence of 
neurotrophin receptor such as p75
NTR  [166–171]. The C-terminal fragment of TeNT drives the 
retrograde transport of the toxin, and can be used to transport heterologous protein in the same 
way [172,173]. Then, TeNT carries out a transynaptic migration and reaches the target neurons, which 
are inhibitory interneurons involved in the regulation of the motoneurons. TeNT enters target 
inhibitory interneurons via vesicles that are acidified thus permitting the delivery of the L chain into 
the cytosol, where it inhibits the regulated release of glycine and GABA. Acidification of the vesicle 
lumen triggers a conformational change of the neurotoxin and subsequent translocation of the L chain 
into the cytosol. H chains form tetramers and insert into lipid membranes, thus forming cation 
selective channels permeable to small molecules (<700 Da). The mechanism of translocation is not 
completely understood. The N-terminal part of H chain mediates the translocation of L chain into the 
cytosol at acidic endosomal pH by modifying the electrostatic interactions with the phospholipids 
without detectable conformational changes. In addition, the disulfide bond between the two chains has 
a crucial role in the translocation process [174–177]. Then, the L chain refolds in the neutral pH of the 
cytosol. Cytosolic translocation factors such as β-COPI are possibly involved in this mechanism, as it 
has been found for diphtheria toxin [41,43,45,178].   
L chains of all clostridial neurotoxins are zinc-metalloproteases that cleave one of the three 
members of the SNARE proteins. TeNT and BoNT/B, D, F and G attack synaptobrevin (or VAMP), 
BoNT/A and E cleaves SNAP25, and BoNT/C1 cut both SNAP25 and syntaxin. The cleavage sites are 
different for each neurotoxin except BoNT/B and TeNT, which proteolyse synaptobrevin at the same 
site. Cleavage of SNARE proteins occurs only when disassembled. Since VAMP, SNAP25, and 
syntaxin play a major role in the regulated fusion of synaptic vesicles with the plasma membrane at the 
release sites, their cleavage induces a blockade of the neurotransmitter exocytosis (Figure 2). 
SNAP25 cleavage by BoNT/A or BoNT/E deeply decreases both SNAP25 and Ca
++ binding to 
synaptotagmin, and subsequently the fusion process of exocytosis (Figure 2) [179–182]. Removal of 
the nine C-terminal amino acids of SNAP-25 by BoNT/A deeply disrupts the coupling between Ca
++ 
sensing and the final step in exocytosis [180]. Truncated SNAP-25 can behave as a dominant negative 
mutant upon the exocytotic process suggesting that after BoNT/A treatment, the block of release is due 
to both functional elimination of SNAP-25 and accumulation of the cleavage product which 
competitively inhibits exocytosis [183–185]. In contrast, blockade of exocytosis by BoNT/E is only 
due to cleavage of SNAP-25, not to the production of competitive antagonists of SNARE complex 
formation. Indeed, inhibition of exocytosis by BoNT/E can be rescued by supplementing the  
C-terminal portion of SNAP-25 removed by the toxin [186–188]. Truncation of SNAP-25 by BoNT/E 
destabilizes the four-helix bundle of the SNARE complex  [186,187], and SNAP-25 truncated by 
BoNT/E is not retained by syntaxin [189]. Toxins 2010, 2                 
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Figure 2.  Schematic representation of the molecular mechanism of evoked 
neuroexocytosis and of toxin-dependent inhibition of neurotransmitter release. Clostridial 
neurotoxins are assumed to enter neuronal cells via synaptic vesicle recycling or by 
classical receptor-dependent endocytosis like C. sordellii LT. Acidification of the 
endosomal lumen triggers the translocation of the catalytic domain (L chain of clostridial 
neurotoxins or N-terminal domain of LT) into the cytosol. Synaptic vesicles loaded with 
neurotransmitter move from a reserve zone to the “active zone” in a close proximity to the 
release sites through an actin filament-dependent manner. Synaptic vesicles association 
with release sites is first driven by interaction of the vesicular GTPase Rab3 with the 
plasma membrane-associated protein Rim (tethering). Subsequent activation of Munc18, 
which triggers the de-chaperonning of syntaxin, leads to SNARE complex assembly 
(priming/docking). Ca
++ entry is sensed by synpatotagmin and triggers the fusion event and 
release of neurotransmitter through Rac-PLD1 activation. Clostridial neurotoxin L chains 
have access to the cleavage sites of SNARE proteins when the SNARE proteins are 
dissociated (physiological window). Cleavage of SNAP25 by BoNT/A or BoNT/C, 
SNARE complex formation still occurs. But, the release of the C-terminal domain of 
SNAP25 impairs the interaction between SNAP25 and Ca
++ to synaptotagmin thus 
preventing the fusion. Truncation of SNAP25 by BoNT/E or VAMP by BoNT/B, BoNT/D, 
BoNT/F or TeNT destabilizes or leads to non functional SNARE complexes. LT acts 
differently by glucosylating and thus inactivating Rac and subsequently preventing the 
PLD1 production of fusogenic phosphatidic acid. 
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VAMP cleavage abolishes the interaction of VAMP with the adaptor protein AP3 and affect 
synaptic vesicle recycling via early endosomes [190]. The SNARE cleavage products have also the 
potential to interfere with fusion processes  [179,191]. Consistent with synaptophysin-1 controlling 
specifically the targeting of VAMP2 but not VAMP1 to synaptic vesicles, is the observation that the 
cytosolic cleavage product of VAMP2 but not VAMP1, released upon TeNT or BoNT/B activity, 
blocks the neurotransmitter release [191]. This result suggests an alteration of the exocytosis due to a 
disturbance of synaptophysin-1/VAMP2 interaction and of coupling between detecting Ca
++ and 
synaptic vesicle triggering [180]. Since the synaptic vesicles docked with unproductive complexes 
cannot fuse or undock, they stay at the fusion sites (with slightly increased numbers) irreversibly 
plugging the fusion sites that would normally accommodate intact vesicles. This progressively reduces 
the number of release sites to which exocytosis can occur as recently demonstrated for TeNT at 
identified Aplysia cholinergic synapses [36]. When VAMP is cleaved by TeNT, BoNT/B or /G, the 
VAMP portion (~20 amino acids) remaining in the synaptic vesicle membrane does not contain 
interaction sites for the other SNAREs. Therefore, the synaptic vesicle membrane is no longer linked 
to a SNARE complex, and fusion with the plasma membrane cannot occur. When VAMP is cleaved 
by BoNT/D or /F, the C-terminal fragment remaining in the vesicle membrane is long enough to 
anchor the synaptic vesicle to the SNARE complex, but fusion cannot occur because the SNARE 
complex cannot transit into the thermally stable four-helix bundle (Figure 2).   
BoNT/C cleaves both syntaxin-1 and SNAP-25, but in vitro cleavage of SNAP-25 by BoNT/C 
occurs with low efficiency (~1000-fold difference) versus cleavage by BoNT/A or /E [192,193]. This 
raises the question which of the two targets is involved in BoNT/C neuroexocytosis blockade? In squid 
giant synapses, BoNT/C cleaves syntaxin-1, but not SNAP25 [194], whereas in cultured hippocampal 
slices or spinal neurons from mammal, BoNT/C efficiently removes nearly all SNAP25 [195,196]. 
Thus, depending on the cell type, the secretory blockade is likely due to syntaxin and/or SNAP-25 
cleavage. Upon syntaxin cleavage, SNARE complexes are formed, but loosely docked to plasma 
membrane, thus synaptic vesicles remain tethered to plasma membrane and cannot fuse [44].   
Although the physiological properties induced by the cleavage of either VAMP, SNAP25 or 
syntaxin are not equivalent at the neuromuscular junctions, all the clostridial neurotoxins cause a 
blockade of the regulated neurotransmission, which varies in intensity and duration according to each 
neurotoxin type. TeNT and BoNT/B share the same molecular mechanism. They are translocated in 
different subset of neurons (excitatory neuron: BoNTs >> TeNT; inhibitory neurons:   
TeNT >> BoNTs) produce strongly different symptoms. This induces different clinical signs (TeNT: 
spastic paralysis; BoNTs: flaccid paralysis). Indeed the peripheral dysautonomia and flaccid paralysis 
caused by BoNTs result from preferential inhibition of acetylcholine release. In the spinal chord or 
facial motor nuclei, TeNT-mediated blockade of glycine or GABA release disrupts the negative 
controls exerted by the inhibitory interneurons onto the motoneurons turning on excessive firing of the 
motoneurons and ensuing muscle contraction [42,44,45,197]. 
3.1.3. Duration of intoxication 
The main factor governing the duration of intoxication is the BoNT toxinotype. The half-lives of 
exocytosis blockade in rat cerebellum neurons are more than 31 days for BoNT/A, more than 25 days 
for BoNT/C1, about 10 days for BoNT/B, about two days for BoNT/F and less than one day for Toxins 2010, 2                 
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BoNT/E, and these durations correlates with the paralysis duration  [97,198,199]. The factors 
governing the toxin longevity within the nerve terminals are not fully unraveled, yet presence of a  
N-terminal sequence and a C-terminal dileucine motif in BoNT/A L chain, and not in the other 
toxinotypes, may explain the retention of BoNT/A L chain to the plasma membrane  [200]. Other 
factors should be considered: in contrast to BoNT/E truncation, SNAP25 lacking nine C-terminal 
residues, released by BoNT/A proteolysis, remains localized at the membrane in association with 
syntaxin. Therefore, unproductive SNARE complex at the active zone induces long-term impeding of 
synaptic vesicle fusion, whereas SNAP25 cleaved by BoNT/E cannot bind to syntaxin and is released 
into the cytosol [189,200]. 
To summarize, despite the scenario that the blocking actions of the various BoNTs differ at the 
molecular level, they all share several commonalities. Indeed, in all cases following toxin action, the 
formation or stability of the SNARE complex is compromised [201,202], and it is no longer fusogenic. 
Thus, synaptic vesicles remain docked at the fusion sites with slightly increased numbers, suggesting 
that when tethered to the plasma membrane or docked in an unproductive complex, not only 
exocytosis but also undocking cannot proceed. Therefore, it is likely that synaptic vesicles docked with 
unproductive complexes can irreversibly plug the fusion sites that would normally accommodate  
intact vesicles. 
3.1.4. Other consequences of SNARE cleavage 
SNAREs are able to interact, directly or indirectly, with other proteins present in the plasma 
membrane. Their cleavage would indirectly affect the functioning of their partners. For example, 
syntaxin promotes inactivation of N- or P/Q-, R-, L-types Ca
++ channels, and this inactivation is 
removed when proteins of the fusion complex (SNAP-25, VAMP, synaptotagmin…) bind to syntaxin 
and/or Ca
++-channels  [203–206]. In this line, SNAP-25 has been reported to control calcium 
responsiveness to depolarization  [122]. Syntaxin cleavage may indirectly alter Ca
++-channel 
functioning: slow Ca
++ influx is potentiated after BoNT/C [207], while in Torpedo preparations, Ca
++ 
entry was reported to be significantly decreased by BoNT/C [208]. Moreover, BoNT/C abolishes the 
regulation of Ca
++-channel by heterotrimeric G-proteins  [209]. SNAP-25 modulates L-Type 
channels [210], and entry of Ca
++ mediated by store operated-channels in pancreatic acini secreting 
amylase, or human platelets. In these cells, Ca
++ influx is strongly depressed after SNAP-25 cleavage 
by BoNT, possibly contributing to the blockade of Ca
++-dependent exocytosis by BoNT/A [130]. Note 
however that these non-neuronal effects have been detected using very high concentration of toxin 
(~100 nM). Overall, these observations suggest that in certain preparations, the blockade of secretion 
resulting from SNAP-25 cleavage can be related to inhibition of the exocytotic machinery and changes 
in Ca
++ influx at the nerve terminals. A significant reduction of the store operated Ca
++ entry (SOCE) 
due to BoNT/A has been observed in different cells. SOCE normally follows a depletion of 
intracellular Ca
++ stores ant this Ca
++ influx is carried out by store-operated Ca
++ channels 
(SOCC) [108,211,212]. Working with Xenopus oocytes, Yao et al. demonstrated that the activation of 
a store-operated Ca
++ current requires SNAP-25, since the current was found to be inhibited by 
BoNT/A in a dose-dependent manner with an apparent Ki of 8 nM. Similarly, the store-operated Ca
++ 
current was almost completely abolished by expression of C-terminal truncated SNAP-25 
mutants [213]. BoNT/A L chain and TeNT significantly reduce SOCE when directly microinjected in Toxins 2010, 2                 
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human embryonic kidney (HEK) cells  [214]. SOCE is also significantly reduced by BoNT/A or 
BoNT/E in murine pancreatic acinar cells and in human platelets [130,131]. The molecular identity of 
the channel carrying the Ca
++ current in SOCE is in the process of clarification, then, it remains 
difficult to assert a role to SNAP-25 in the regulation of the conductance or in the process of protein 
secretion. A direct interaction of SNAP-25 with TRPC1 channel has been postulated [215] and, more 
recently, the inhibition of exocytotic-like insertion of Orai1 into the plasma membrane in human HeLa 
and HEK 293T cells has been shown to be partially affected by BoNTA [216]. Likewise, physical and 
functional interactions between syntaxin 1A and brain voltage gated K
+ -channels Kv1.1 type have 
been found [217]. The activity of Kv2.1 channel, the prevalent delayed rectifier channel in endocrine 
and neuroendocrine cells, is also strongly modulated by syntaxin and SNAP-25  [218,219]. This 
suggests that SNARE proteins can regulate membrane excitability via  K
+ channels, thus tuning 
exocytosis. This raises the question of whether exocytosis may be altered by BoNTs via changes in 
activation of Kv2.1 currents. 
3.1.5. Non-proteolytic molecular actions of BoNTs and TeNT 
Yet a direct cause-effect relationship exists between the cleavage of the SNAREs and the blockade 
of neuroexocytosis by BoNTs or TeNT [41,44,220]. A controversial possibility is that BoNTs and 
TeNT may interfere with exocytosis and other cell functions via molecular actions unrelated to their 
proteolytic activity. Indeed, when mutated in the catalytic site at positions crucial for either Zn
++ 
binding (His233 and His237) or cleavage of the Gln-Phe bond in VAMP-2 (Glu234), TeNT L chain 
cannot cleave VAMP-2 in vitro  [221,222]. However, several of point-mutated TeNT L chain 
constructs are able to produce inhibition of neurotransmitter release (His233- > Ala233, Leu233 or 
Val233; Glu234- > Ala234; His237- > Ala237; Asp237, Gly237 or Val237) albeit with reduced 
potency as compared to wild-type TeNT L chain [223,224]. Such a non-proteolytic mechanism may 
explain why endopeptidase blockers, which abolish VAMP-2 cleavage in vitro, counteract only 
partially the inhibitory action of TeNT on neurotransmitter release  [223,225]. Moreover, the 
observation that antagonism of the intracellular action of BoNT/A can be relieved fast by the mean of 
injecting monoclonal antibodies directed against the BoNT/A L chain [226] is difficult to conciliate 
with the proteloytic activity of the neurotoxin protein cleavage being in essence irreversible. The 
observation that TeNT binds with high affinity to, and strongly activates the GTP-binding protein 
transglutaminase type II (TGase II) in vitro, suggests that TGase II may participate in the intracellular 
action of TeNT  [227,228]. However, the precise contribution of TGase II to the blockade of 
neurotransmission by TeNT has never been clarified and conflicting data exist in the 
literature  [223,229,230]. TGase II belongs to a large family of bifunctional and Ca
++-dependent  
cross-linking enzymes [231,232] abundant in neurons and nerve endings [228,233] which has been 
implicated in secretory mechanisms [234–236].   
The identification of the vesicular protein synapsin-I as one of the two main substrates crosslinked 
by TGase II needs to be considered for explaining part of the nonproteolytic TeNT-induced decrease in 
neurotransmitter release. Indeed, synapsin-I regulates synaptic vesicle trafficking via interactions with 
the actin cytoskeleton and participates in post-docking steps of exocytosis [237,238]. Possibly, TeNT 
stimulation of TGase II leads to reduced synaptic vesicle availability for release. This view is 
supported by several observations: (i) the depolarization-stimulated phosphorylation and redistribution Toxins 2010, 2                 
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of synapsin-I is altered after the action of TeNT [239]; (ii) the blocking action of TeNT is diminished 
after disassembly of microfilaments  [150] and (iii)  the amplitude of post-tetanic potentiation, a 
plasticity paradigm which involves synapsin-I in Aplysia  synapses, is highly reduced after TeNT 
treatment  [36,237]. As TeNT can access VAMP-2 only during a defined “physiological 
window” [41,44],  TGase-II  activation may modulate this access via  the modification of proteins 
involved in regulation of the synaptic vesicle cycle (i.e., synapsin I) or its other substrate(s).   
The importance of the proteolytic and non-proteolytic mechanisms of TeNT may be variable from 
one model systems to other, and may depend on differential expression of endogenous TGase-II. 
Contrasting with the observations made using brain synaptosomes or Aplysia preparations [223,224], 
non-proteolytic TeNT mutants have been found ineffective at the mouse hemidiaphragm  [221] or 
neurohypophysial nerve endings  [240] and participation of TGase-II activation in the blockade of 
secretion by TeNT has been ruled out at the mouse neuromuscular junction and in NG108 cells [229]. 
In vitro, BoNT/E light chain has been reported cleaving actin and all the 11 cleavages sites identified 
involved Arg or Lys residues in P’1 position exactly as in SNAP-25 [241]. Thus another unexpected 
intracellular effect of TeNT is the modification of actin cytoskeleton. This is supported by several 
observations: TeNT inhibits the rearrangements of subcortical microfilaments that accompany 
secretion in chromaffin cells  [242]. Actin cytoskeleton network is altered when TeNT L chain is 
expressed in Sertoli cells in mice [243]. Consistent with the well documented implication of small 
GTPases Rho in the dynamics and organization of actin-based cytoskeleton [24], BoNT/A has been 
reported to target RhoB to the proteasome, causing both blockade of exocytosis and actin 
cystoskeleton disorganization  [244]. This may relate to a crosstalk between actin cytoskeleton 
remodeling, SNARE- and Rho-GTPase-dependent mechanisms of exocytosis, as illustrated for Cdc42 
and VAMP-2 during insulin secretion [245].   
TeNT shows unconventional cellular action time before its classical proteolytic effects became 
evident. Aguliera and Yavin first reported the in vivo activation and translocation of protein kinase C 
in rat brain [246]. Concomitantly, an increase of phosphoinositide hydrolysis was observed [247]. The 
intracellular pathway activates phospholipase C-1 and other kinases [248]. Among the different targets 
these enzymes can attain, the best characterized is the 5-HT transporter which is phosphorylated and 
has its activity modulated at low toxin concentration (10
–12 M) in less than 30 minutes [155,157,158]. 
These effects are carried out by the half C-terminal part of the H chain, the portion that carries the 
binding domain of the toxin to the receptor [249,250]. It is of interest to note that this portion of the H 
chain is able to protect from death neuronal cells, in vitro as well as in vivo [250–252]. Indeed, TeNT 
Hc activates phosphatidylinositol 3-kinase (PI-3K)/Akt (a serine/threonine kinase) as well as 
extracellular-signal regulated kinases 1 and 2 (ERK-1/2) pathways through phosphorylation of tyrosine 
kinase receptor leading to protection of apoptosis by preventing the proteolytic activation of  
pro-caspase-3, cytochrome c release from mitochondria, and chromatin condensation [249,251,253]. 
Interestingly, TeNT Hc prevents apoptosis induced by 1-methyl-4-phenylpyridinium (MPP+), which is 
a mitochondrial poison used to reproduce a Parkinson-like disease  [251]. Since TeNT Hc is 
retrogradely transported to the central nervous system it could be used in the prevention/treatment of 
the Parkinson's disease. In vivo in a rat model of Parkinson's disease, TeNT HC has been found to 
improve the dopaminergic system and to enhance the survival rate [252]. 
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3.2. Toxins which inactivate Rho-GTPases and inhibit neuroexocytosis 
3.2.1. Glucosylating clostridial toxins 
Glucosylating clostridial toxins, also known as the large clostridial toxins such as Clostridium sordellii 
lethal toxin (LT) and Clostridium difficile toxin A (ToxA) and toxin B (ToxB), inactivate Rho-and/or 
Ras-GTPases by modifying a conserved threonine within the effector domain of target molecules. 
ToxB catalyzes glucosylation of Rho proteins (Rho, Rac, and Cdc42), whereas the several variants of 
LT modify Rac, sometimes Cdc42, and various Ras proteins (i.e., Ras, Rap, Ral). C. difficile and  
C. sordellii toxins use UDP-glucose as cosubstrate, and Clostridium novyi α-toxin uses   
UDP-N-acetylglucosamine. GDP-bound GTPase is the preferred substrate, since the modified Thr35 
and Thr37 residues are only exposed on the surface of this GTPase form.  
Although glucosylated GTPases can bind to their target membrane and undergo GDP-GTP 
exchange when stimulated by guanylate exchange factors, modification of Thr37/35 which is localized 
within switch I of GTPases, prevents the interaction with their effectors. In addition, intrinsic GAP 
(GTPase activating protein)-stimulated GTPase activity is reduced, inhibiting the GDP-GTP cycling of 
modified GTPases between the membrane and cytosol. Thereby, glycosylated GTPases act as dominant 
negative mutants [254–260]. 
C. botulinum C3 enzyme is an ADP-ribosyltransferase, which specifically inactivates Rho.   
C3 ADP-ribosylates Asn41, which is localized within the switch I loop near Thr37. C3-mediated 
ADP-ribosylation of Rho inhibits the GTPase translocation to the membrane and therefore prevents the 
interaction with its effectors. ADP-ribosylated Rho is trapped by guanine dissociation inhibitor (GDI) 
in an inactive, cytosolic form [24,260–262]. 
3.2.2. Neuronal alterations caused by toxin inactivation of Rho GTPases 
Several small GTPases of the Ras superfamily are present in nerve terminals and include RhoA, 
RhoB, Rac1, and Cdc42. Additionally, Rac1 associates with synaptic vesicles as well as with plasma 
membrane [27,28]. The Ral molecule also binds to synaptic vesicles [31]. Intraneuronal application of 
C3 exoenzyme, ToxB from C. difficile, or LT from C. sordellii blocks Ca
++-dependent vesicular ACh 
release from Aplysia synapses [27,28]. LT exhibits the highest activity upon neurotransmitter release, 
being 100–1,000 fold more potent than ToxB or the C3-exoenzyme  [27]. Similarly, LT blocks 
spontaneous glutamate release in cultured rat cerebellar slices (Kojima and Poulain, unpublished 
observation). These observations are consistent with reports that Rho-acting toxins block the secretory 
process in many cell types, including mast cells [263–266]. In muscles isolated from mice previously 
injected with LT, nerve-evoked muscle twitch is blocked. This effect results from both a presynaptic 
block of ACh release and depressed muscle contractility [267].  
This is consistent with the high lethality of LT (~0.3 × 10
6 mouse LD50/mg protein) injected 
intraperitoneally, which is due to respiratory failure [268]. Because of the potent blocking action of LT 
on nerve endings, a question arises whether the intestinal disorders which characterize enterotoxemia 
caused by clostridia producing Rho-acting toxins are linked to intestinal epithelial damage and/or 
stimulation of the enteric nervous system [269]? Identity of the downstream pathways whose silencing 
blocks exocytosis induced by LT or ToxB has been addressed in different cell systems. Apparently, the Toxins 2010, 2                 
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affected pathways can vary in different cell types. In several types of secretory cells, experimental 
findings indicate that the toxins induce remodeling of the actin cytoskeleton, thereby altering 
intracellular granule trafficking towards the plasma membrane, which possibly includes 
fusion [265,266]. Another interesting configuration has been deciphered in RBL-mast cells. In these 
cells, exocytosis is triggered by a rise in intracellular Ca
++ levels induced by stimulation of either the 
Fc-epsilon receptor or muscarinic- type AChR. The Rac GTPase is the only one involved in Ca
++ 
mobilization within these cells, and the blockade of exocytosis by ToxB or LT is due to inhibition of 
capacitative Ca
++ entry exclusively through store-operated Ca
++ channels [263,270].  
In nerve endings, the blockade of neurotransmitter exocytosis caused by ToxB and LT appears to 
have another origin. Studies performed with Aplysia  cholinergic synapses reveal that following 
inactivation of Rac by LT or ToxB, the exocytosis process starts normally, but then stops, possibly 
during the priming events. This results in a dramatic decrease in the number of functional release 
sites [28], which is very similar to the gross action of TeNT or BoNTs. What is the role of Rac during 
priming? Rac, Rho, Cdc42, Ral, and PLD1 all participate in a multiprotein complex termed “exocyst,” 
which is comprised of Sec6/Sec8 proteins and regulates polarized secretion as well as docking of 
vesicles to plasma membrane regions specialized in exocytosis [271]. Therefore, one cannot exclude 
that Rho-acting toxins block exocytosis by disabling exocyst function in nerve endings. However, 
implication of an exocyst role during exocytosis of neurotransmitter is disputed. Alike, possibility 
implicating PLD1 in the exocytosis process is that by catalyzing PA generation, the formation of lipid 
bilayer intermediates becomes favored during membrane fusion. PLD1 activity is inhibited in   
LT-poisoned cells  [272], and Rac plus Cdc42 regulate PLD1 activity  [273]. The intraneuronal 
application of a catalytically- inactive mutant of PLD1 reproduces the potent inhibitory effect of 
LT [237]. Therefore, we envisage the following model for LT and ToxB action at the presynapse, 
which initially involves glucosylation of Rac by the toxins, thus preventing activation of PLD1 upon 
synaptic vesicle docking. Production of fusogenic PA is not stimulated, and despite the Ca
++ influx 
triggering SNARE complex zippering, fusion of synaptic vesicle with plasmalemma exocytosis cannot 
occur because the lipid composition at release sites remains inadequate. The synaptic vesicles 
equipped with modified Rac plug exocytosis sites and prevent fusion of synaptic vesicles equipped 
with intact Rac (Figure 2). This contributes to the reduced numbers of active release sites induced by 
LT or ToxB. In addition to the presynaptic actions mentioned above, clostridial cytotoxins affecting 
Rho GTPases can also block neurotransmission by altering postsynaptic cell capabilities to detect 
transmitter. For example, neurotransmitter-receptor density is diminished in neurons treated with 
toxins that affect Rac or Cdc42 [274]. The observation that LT prevents long-term potentiation [275] is 
consistent with inhibiting insertion of new receptors into the post-synaptic membrane. Note that it is 
not yet clear whether changes in receptor density refer to the role of Rho proteins during the exocytotic 
process, which includes receptor insertion into the plasma membrane, and/or organization of the  
post-synaptic actin cytoskeleton involved in receptor clustering [276].  
Much evidence suggests that apoptosis plays a crucial role in cell homeostasis, which depends upon 
the expression of various genes implicated in controlling life and death. Incubation of rat primary 
cerebellar granule neurons in culture with either ToxB or LT reportedly induces cell death with 
biochemical and morphological hallmarks of neuronal apoptosis  [277]. In these cells, selective 
inhibition of Rac/Cdc42 function promotes: (1) phosphorylation and expression of the transcription Toxins 2010, 2                 
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factor c-Jun; (2) activation of caspase-3; and (3) nuclear condensation, as well as fragmentation. 
Interestingly, apoptosis occurs independently of F-actin-cytoskeletal disruption, since agents that 
directly disassemble F-actin (C. botulinum C2 toxin, cytochalasin D, and latrunculin A) do not induce 
cell death within 24 h. These results indicate that Rac/Cdc42 GTPases are critical for survival of 
cerebellar granule neurons in primary culture. Additionally, these data are the first to establish a 
prosurvival function for Rho GTPases in a primary neuronal cell model. 
3.3. Toxins which damage neuronal cells, neuronal apoptosis 
Strpetococcus pneumoniae (or Pneumococcus) is the most common cause of bacterial meningitis, 
which is characterized by neuronal cell death in the hippocampus as well as by an inflammatory 
response. Pneumolysin (PLY) produced by S. pneumoniae, is one of the virulence factors leading to 
neuronal cell damages and which also causes injury to pulmonary alveolar epithelial cells [278]. 
PLY (53 kDa) is a pore-forming toxin from the cholesterol-dependent cytolysin family, the 
prototype of which is the perfringolysin (PFO) from C. perfringens. PLY shares 45% identity at the 
amino acid level with PFO. In contrast to PFO, PLY contains no signal sequence for secretion and is 
released mainly during autolysis of bacteria  [279]. A structural model of PLY based on the high 
similarity with PFO shows that PLY has an unusual elongated rod shape. The molecule is rich in  
β-sheet and it is hydrophilic without significant patches of hydrophobic residues on the surface. Four 
domains can be distinguished in the PFO or PLY molecule. Domain 1 has a seven-stranded antiparallel 
β-sheet and is connected to domain 4 by the elongated domain 2. Domain 3 consists of β-sheets and  
α-helices. The C-terminal part (domain 4) folds into a separate and compact β-sandwich domain, and 
contains three loops (L1-L3), which are involved in the binding to choleterol [280,281].   
A unique Cys is located in a conserved 11 amino acid sequence (ECTGLAWEWWR) near the  
C-terminus, in the domain 4, which participates to the prepore to pore conversion [280,282]. The 
proposed model of PFO pore formation, which is probably similar to that of PLY, includes the binding 
of water soluble PFO monomers to cholesterol of lipid bilayer mediated by the L1-L3 loops from 
domain 4 [280]. But, domain 4 does not insert deeply into the membrane and is not directly involved 
in creating the pore. PFO monomers bound to cholesterol and orientated perpendicularly to the 
membrane assemble and oligomerize to form a prepore complex [283]. Oligomers consist of 40 to 50 
monomers forming on the membrane surface large arcs and rings leading to large pores between 300 Å 
and 450 Å in diameter [284]. Domains 1, 2 and 4 fit into L-shaped repeating units connected to the 
corresponding domains of the neighboring partners and forming a cylindrical structure. Oligomer 
formation results from domain 1-domain-1 interaction via hydrogen bonding between 1-strand of one 
subunit with 4-strand of a second subunit. Interaction of domain 4 with cholesterol induces a 
conformational change of domain 1 causing the moving of β5-strand which prevents 1-4 interaction in 
the soluble PFO form and thus permitting the oligomerization process only when PFO interact with cell 
membrane [285,286]. Thereby, PFO monomers do not oligomerize in solution. In addition, domains 3 
are rotated from domains 2 and form a belt in the outside face of the cylinder. This is accompanied by 
a flexing of domain 2 leading to a loss of many contacts between domain 3 and domain 2 thus 
promoting the exposure of hydrohobic residues and the insertion of a transmembrane β-barrel into the 
lipid bilayer [287–289]. A bundle of three α-helices of domain 3 unfolds forming two amphipathic  
β-sheets. Each monomer contributes two amphipathic β-hairpins to the formation of the transmembrane Toxins 2010, 2                 
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β-barrel  [290,291]. Monomers do not insert their transmembrane hairpins individually, but a 
cooperation between PFO monomers is required to drive the insertion of the prepore complex, which 
appears to be an all or none process [292]. The charged face of domain 4 amphipathic β-hairpin forms 
the inner lining of the pore and the other face is protected from the hydrophobic part of the lipid 
bilayer by cholesterol molecules [293]. Domain 2 collapses vertically of 40 Å allowing the insertion of 
the β-barrel into the membrane and formation of a large membrane pore [294]. 
An initial step in bacterial meningitis is the passage of S. pneumoniae from blood to the brain 
through the blood brain barrier. PLY is probably involved in this process, since PLY expressing strain 
but not PLY negative mutant is able to penetrate into microvascular endothelial cells. The mechanism 
of PLY-dependent translocation of bacteria across the cell barrier is possibly based on loss of cell 
viability and cell detachment [278,295]. Subsequently in the central nervous system, PLY directly 
induces hippocampal neuronal cell death via an apoptotic process. Indeed, PLY was found to 
colocalize with damaged neurons in the hippocampus and to mediate microglia and neuronal cell 
apoptosis in vitro [296]. The PLY pore-forming activity is required to trigger apoptosis in primary 
hippocampal neurons, whereas the PLY domain involved in complement activation is not required. 
The PLY-dependent pathway leading to neuronal cell apoptosis includes an increase in Ca
++ into the 
cytosol subsequently to an influx from extracellular space and a release from endoplasmic-reticulum 
stores, mitochondrial damages with release of cytochrome c and AIF (apoptosis inducing factor) and 
then DNA fragmentation [296,297]. The increase in intracellular Ca
++ seems to be mainly mediated by 
toxin-dependent pore formation in cell membranes and is followed by an activation of p38 MAPK 
(mitogen-activated protein kinase) and possibly by opening of the mitochondrial permeability 
transition pore leading to AIF release [298]. However, PLY also directly interacts with mitochondria 
as evidenced by colocalization of PLY with mitochondrial membranes, and can possibly directly forms 
pores in mitochondria. PLY apoptosis is caspase-independent and is mediated by the release of 
mitochondrial AIF, which is a potent caspase-independent cell death factor [296,297]. Thus PLY is a 
pore-forming toxin inducing apoptosis in hippocampal neuronal cells in addition to damages caused in 
other cell types. 
4. Toxins Which Stimulate Neurosecretion 
4.1. Stimulation of glutamate release: Clostridium perfringens epsilon toxin 
Epsilon toxin acts on different cell types, including those of neuronal origin. It is not a strict 
neurotoxin as defined previously for BoNTs and TeNT, but epsilon toxin is involved in neurological 
symptoms. Epsilon toxin represents the major virulence factor of C. perfringens types B and D, which 
are the etiological agents of fatal enterotoxemia in sheep as well as goats, and more rarely of cattle. 
Overgrowth of C. perfringens in the intestine of susceptible animals, generally a consequence of 
overeating high starch/sugar-containing foods, results in large amounts of epsilon toxin. The toxin is 
absorbed through the intestinal mucosa by opening tight junctions between intestinal epithelial cells 
and spreads into different organs by the circulatory system [299,300], ultimately causing hypertension, 
increased vascular permeability, lung edema, and post mortem kidney necrosis (pulpy kidney disease 
in lambs) [260,301,302]. The disease is rapidly fatal with neurological disorders that include excitation 
symptoms. Major pathological changes are observed in the brain following epsilon intoxication, which Toxins 2010, 2                 
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include: congestion and edema of the meninges, perivascular and intercellular edema, as well as 
necrotic foci of the nervous tissue. Epsilon toxin passes through the blood brain barrier and 
accumulates specifically in the brain [303,304]. The toxin damages endothelial cells of the blood-brain 
barrier by altering the endothelial barrier antigen localized to luminal endothelial cell membranes, thus 
causing leakage of endogenous albumin [305]. The specific receptor for epsilon toxin on neuronal and 
endothelial cells is not yet known, although a membrane sialoglycoprotein seemingly mediates toxin 
binding  [304,306]. In the brain, epsilon toxin increases vascular permeability leading to a rapid, 
severe, and diffuse edema that exerts a direct cytotoxic effect upon neurons. Neuronal damage is 
characterized by progressive cytoplasmic vacuolization plus necrosis, and in some cells there is 
hyperchromatosis and nuclear pyknosis  [307]. The neurological disorders linked to epsilon toxin, 
which likely result from an excessive release of glutamate, include retraction of the head, opisthotonus, 
convulsions, agonal struggling, and hazardous roaming. Indeed, epsilon toxin injected intravenously 
into mice preferentially excitates hippocampal neurons that induce an increased glutamate efflux 
which can be blocked by a specific inhibitor [308,309].  
The molecular basis for epsilon neurotoxicity is not known, but the toxin is a pore former, which 
structurally mimics Aeromonas hydrophila aerolysin [310]. Epsilon-toxin retains an elongated form 
and contains three domains, which are mainly composed of β-sheets. The overall structure is 
significantly related to that of the pore forming toxin aerolysin. The main difference between both 
toxins is that the aerolysin domain I, which is involved in initial toxin interaction with cells, is missing 
in epsilon-toxin. Domain 1 of epsilon-toxin consists in a large α-helix followed by a loop and three 
short  α-helices and is similar to domain 2 of aerolysin which interacts with the GPI anchors of 
proteins. This domain of epsilon-toxin could have a similar function of binding to receptor. Domain 2 
is a β-sandwich structurally related to domain 3 of aerolysin. This domain contains a two-stranded 
sheet with an amphipatic sequence which is the channel-forming domain [311]. Domain 3 is also a  
β-sandwich analogous to domain 4 of aerolysin and contains the cleavage site for toxin activation. 
Domain 3 after removing of the C-terminus is likely involved in monomer-monomer interaction 
required for oligomerization [312]. 
In Madine Darby Canine Kidney (MDCK) cells, which is a rare cell line sensitive to epsilon toxin, 
the toxin recognizes a specific unknown receptor, heptamerizes, and forms pores that lead to an efflux 
of K
+, influx of Na
+, Cl
− and Ca
++, cell swelling, and membrane blebbing/disruption [313–315]. In 
addition, epsilon toxin rapidly decreases membrane barrier permeability of polarized MDCK 
cells  [316]. Epsilon toxin also forms heptamers in synaptosomal membranes  [313,317], which 
involves detergent resistant membrane microdomains called lipid rafts. But it is not yet defined 
whether the toxin-induced glutamate release is due to pore formation or another specific mechanism. 
The epsilon toxin-dependent cytotoxicity is associated with a rapid loss of intracellular K
+, and an 
increase of Cl
− and Na
+, whereas the increase of Ca
++ occurs later. In addition, the loss of viability also 
correlates with the entry of propidium iodide, indicating that the epsilon-toxin forms large pores in cell 
membrane. Pore formation was evident in artificial lipid bilayer. Epsilon-toxin induces water-filled 
channels permeable to hydrophilic solutes up to a molecular mass of 1 kDa, which represent general 
diffusion pores slightly selective for anions [315]. In polarized MDCK cells, epsilon-toxin induces a 
rapid and dramatic increase in permeability. Pore formation in the cell membrane is likely responsible 
for the permeability change of cell monolayers. Actin cytoskeleton and organization of tight and Toxins 2010, 2                 
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adherens junctions are not altered, and the paracellular permeability to macromolecules is not 
significantly increased upon epsilon-toxin treatment [318,319]. Epsilon toxin causes a rapid cell death 
by necrosis characterized by a marked reduction in nucleus size without DNA fragmentation. Toxin-
dependent cell signaling leading to cell necrosis is not yet fully understood and includes ATP 
depletion, AMP-activated protein kinase stimulation, mitochondrial membrane permeabilization, and 
mitochondrial-nuclear translocation of AIF  [319]. Therefore, epsilon-toxin is a very potent toxin, 
which alters the permeability of cell monolayers such as epithelium and endothelium causing edema 
and cell death and which induces glutamate release from hippocampal neuronal cells. 
4.2. Stimulation of serotonin release and other neuromediators from the enteric nervous system 
Increasing evidence suggests that some enterotoxins mediate diarrhea by not only acting directly 
upon enterocytes, but also by interfering/stimulating the enteric nervous system [269]. The enteric 
nervous system is comprised of the myenteric plexus which is primarily involved in motor control of 
the gut and of the submucosal plexus, which plays a central role in sensing the chemical status of the 
intestine and in regulating secretion. Neuronal cell bodies of the enteric nervous system (intrinsic 
afferent neurons, interneurons, motor- and secretory-neurons) are clustered in ganglia and connected to 
parasympathetic and sympathetic systems. More than 20 neurotransmitters have been identified in the 
enteric nervous system. Among them, substance P, ACh, GABA, glutamate, and 5-HT modulate 
motility, absorption, and secretion of the intestine [320,321]. 
4.2.1. Bacterial enterotoxins inducing increased intestinal secretion 
4.2.1.1. Cholera toxin 
Cholera toxin (CT) is produced by Vibrio cholerae and is responsible for cholera, which is a serious 
epidemic disease characterized by severe diarrhea and dehydration. CT consists of an A or enzymatic 
subunit (28 kDa), and 5 B or binding subunits (11 kDa each) assembled in a pentamer (AB5 structure). 
The A subunit is proteolytically activated by a V. cholerae endopeptidase into two components A1 
(approximately 22 kDa) and A2 (approximately 5.5 kDa) which remain linked by a disulfide bridge. 
The carboxy-terminal part of A2 extends through the central pore of the B pentamer and is linked  
non-covalently to the B subunits. Heat labile enterotoxin (HLT) from Escherichia coli is highly similar 
to CT, 88% amino acid sequence homology and closely related crystalline structure [322]. However, 
LT induces a much less severe type of diarrhea. 
Both toxins, CT and HLT, recognize the glycosphingolipid GM1 on enterocyte membrane. CT 
entry into cell and intracellularr trafficking has been extensively studied. The whole toxin bound to 
GM1 receptors is then internalized into endocytic vesicles [323]. GM1 directs the toxin into lipid-rafts 
from where it enters the Golgi via early and late endosomes [324]. CT enters cells via multiple ways 
including clathrin-dependent and –independent pathways. But transport of CT from plasma membrane 
to Golgi is mainly mediated by endosomes containing caveolin-1 and is independent of clathrin 
coated-pits [325]. In the perinuclear region of the Golgi, the A subunit dissociates from the B subunits 
and enters the endoplasmic reticulum via coatomer I-coated vesicles and uses the cell secretion system 
Sec60/61. The carboxy-terminal sequence of the A2 fragment contains an endoplasmic reticulum (ER) Toxins 2010, 2                 
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retention sequence (KDEL), which may rather function to efficiently retain the toxins in the ER, 
allowing the A1 chain to be transported into the cytosol [326,327]. 
The A1 fragment is responsible for the enzymatic activities of the toxin, including NAD hydrolysis 
in ADP-ribose and nicotinamide, and covalent transfer of ADP-ribose to Arg-187 of the subunit of 
stimulatory protein (Gs leading to stimulation of adenylate cyclase and elevated intracellular 
cAMP  [324]. The increased cAMP levels induces an activation of protein kinase A, which 
subsequently phosphorylates numerous substrates in the cell including the major chloride channel 
called the cystic fibrosis transmembrane conductance channel (CFTR). This results in an active  
Cl− secretion and a decrease of NaCl-coupled absorption by enterocytes [322,324]. 
But in addition, CT stimulates 5-HT release from enterochromaffin cells primarily localized at the 
base of the epithelial crypts of the intestine, probably via its effect on adenylate cyclase activation. 
Increased intracellular cAMP activates Ca
++ influx through L-type calcium channel resulting in 
exocytosis of 5-HT containing granules [328]. Indeed, an increased 5-HT release into the intestinal 
tissue and lumen was evidenced in response to CT in human and animal models, as well as an 
inhibition of CT-dependent intestinal secretion by pharmacological inhibitors of 5-HT receptors. A 
direct binding of CT to enterochromaffin cells seems to trigger the degranulation and 5-HT 
release  [329]. Thus, 5-HT2, 5-HT3 and 5-HT4 receptors have been found to be involved in   
CT-mediated intestinal secretion [329–334]. 5-HT receptors are classified in seven families and are 
distributed on enterocytes, myocytes and neurons of the gastrointestinal tract. Except the 5-HT3 
receptor, which is a ligand-gate ion channel, the other 5-HT receptors are seven-transmembrane 
domain G-protein-coupled receptors. 5-HT2 receptors are located to myenteric and submucosal 
neurons, enterocytes, and longitudinal and circular muscle cells of the gastrointestinal tract. They 
participate to intestinal motility and to intestinal secretion via an arachidonic pathway. 5-HT3 receptors 
are expressed in neurons of myenteric and submucosal plexus, interstitial cells of Cajal, and muscle 
fibers of circular and longitudinal muscles, as well as in submucosa and mucosa. Activation of 5-HT3 
receptors results in gastrointestinal contractions and intestinal chloride secretion, and in 5-HT release 
from enterochromaffin cells. 5-HT4 receptors have been identified in submucosal and myenteric plexus 
as well as in nerve fibers of intestinal circular muscles. 5-HT4 receptors have an important role in 
gastrointestinal functions such as activation of gastrointestinal motricity via enhancement of ACh and 
CGRP release as well as stimulation of chloride and bicarbonate secretion by enterocytes [335]. 
Therefore, CT-induced intestinal secretion is mediated by 5-HT release from enterochromaffin cells 
and in part from enteric neurons by the toxin (Figure 1). Released 5-HT induces water and electrolyte 
secretion via stimulation of 5-HT2 receptors on enterocytes and via activation of secretory reflex(es) 
through the enteric nervous system. 5-HT activates afferent sensory nerves mainly through stimulation 
of 5-HT3 and 5-HT4 receptors. These afferent neurons, probably from the submucosal plexus, contain 
ACh/substance P, ACh/CGRP, and dynorphin or glutamate as neurotransmitters. They project to the 
myenteric plexus and are also directly connected to secretomotor neurons  [336–338]. Indeed,   
CT-induced secretion can be blocked by the ACh nicotinic receptor antagonist hexamethonium, by 
substance P antagonists as well as by inhibitors of substance P receptors such as neurokinin-1 and 
neurokinin-2 [5,338].  
Cholinergic interneurons and possibly other interneurons containing other neurotransmitters 
probably connect the myenteric and the submucosal neurons of the reflex, which subsequently Toxins 2010, 2                 
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stimulate efferent secretory neurons releasing VIP and possibly nitric oxide (NO). VIP is a potent 
intestinal secretagogue, which recognizes specific receptors belonging to the type B G-protein coupled 
receptor family, on the basolateral membrane of crypt cells as well as of many other cell types, and 
induces an adenyl cyclase-cAMP-dependent secretion of NaCl and water. VIP triggers increase in 
cAMP level only in crypt cells and not in villus cells. cAMP activates protein kinase A and 
subsequently a phosphorylation cascade leading to stimulation of the apical CFTR channel and 
chloride secretion [5,336]. Antagonists of 5-HT, substance P and VIP markedly reduce CT-induced 
secretion  [320,337,338]. In addition, ACh is a calcium-dependent chloride secretagogue through 
activation of muscarinic receptors such as M3 or possibly through a direct delivery into epithelial cells 
and seems to be also involved in the CT induced intestinal secretion [5]. Therefore, CT probably 
stimulates the two types of efferent neurons of the intestinal secretory reflex pathway, cholinergic and 
VIP neurons contributing to the toxin induced diarrhea (Figure 3). 
Interestingly, E. coli HLT does not stimulate the release of 5-HT from enterochromaffin cells. 
Thereby, HLT-induced secretion is not inhibited by inhibitors of 5-HT or substance P. However, 
lignocaine and the ganglionic blocker hexamethonium have a preventive effect, suggesting that the 
entero nervous system is also involved in the enteric activity of HLT, but via a distinct pathway than 
that mediated by 5-HT. Although highly related to CT, HLT exhibits significant structural differences 
and recognizes a low affinity glycoprotein receptor. This might account for the non activation of 
enterochromaffin cells by HLT and the 5-HT-mediated intestinal secretion induced by CT explains, at 
least partially, the severity of cholera versus the more moderate diarrhea caused by HLT [320,329]. 
4.2.1.2. Enterotoxins modifying the actin cytoskeleton or inducing an intracellular second messenger  
C. difficile toxin A (ToxA; ~300 kDa) is a potent enterotoxin responsible for pseudomembranous 
colitis. In addition to the apparent actin-cytoskeleton alterations in enterocytes like ToxB, ToxA 
probably uses a neural mechanism to increase intestinal secretion (Figure 3). Lignocaine, 
hexamethonium, and substance P inhibitors can block Tox A-induced ileal fluid accumulation, 
mucosal permeability, and inflammation [339]. It is proposed that ToxA stimulates primary sensory 
neurons in the intestinal mucosa, causing subsequent release of substance P and CGRP, which then 
facilitates intestinal secretion and inflammation. These neuropeptides bind to macrophages in the 
lamina propria and activate the release of proinflammatory cytokines such as tumor necrosis factor 
(TNF) [269,340]. Thereby, ToxA stimulates intestinal macrophage expression of neurokinin-1, which 
is a high affinity receptor for substance P, and additionally neurokinin-1 deficient mice are protected 
from ToxA-induced intestinal secretion and inflammatory diarrhea  [341]. Neurotensin, a 
gastrointestinal neuropeptide, is also involved since an inhibitor of neurotensin prevents the secretory 
and inflammatory responses following ToxA exposure  [342]. Furthermore, ToxA also suppresses 
noradrenaline release at sympathetic synapses of the enteric nervous system that play an inhibitory 
effect on secretomotor neurons, thus amplifying mucosal secretion [343]. It is not yet clear whether 
ToxA directly stimulates intestinal sensory neurons by a mechanism involving Rho proteins, or 
indirectly via inflammatory mediators released from enterocytes or other cells such as macrophages in 
response to ToxA. 
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Figure 3. Schematic model of the neuronal reflex controlling the intestinal secretion and 
alteration by enterotoxins. Cholera toxin (CT) triggers the release of serotonin (5-HT) from 
enterochromaffin cells, mainly located in intestinal crypts, which stimulates enterocyte 
secretion through 5-HT2 receptors and activates afferent sensory neurons through 5-HT3, 5-
HT4 receptors. The neuronal signal is relayed through the submucosal and myenteric 
plexuses leading to activation of secretomotor neurons including acetylcholine (ACh) and 
vaso-intestinal peptide (VIP) neurons. ACh stimulates M2 receptors on enterocytes and 
VIP recognizes specific enterocyte receptors. The neuronal-dependent intestinal secretion 
is negatively regulated by noradrenergic and enkephalinergic neurons. C. difficile ToxA 
stimulates primary sensory neurons leading to the release of substance P (SP) and 
calcitonin gene-related protein (CGRP) and subsequently causing intestinal secretion and 
inflammation. ToxA first interacts with intestinal epithelial cells causing actin cytoskeleton 
alteration and release of cytokines, which are probably the stimulators of primary sensory 
neurons. In addition, ToxA attenuates the inhibitory response of noradrenergic and 
enkephalinergic neurons. The precise ToxA pathway permitting its interaction with the 
enteric nervous system is not yet known. 
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C. perfringens enterotoxin (CPE) is responsible for the food borne intoxication due to this 
bacterium. CPE is synthesized during the sporulation of C. perfringens and is a pore-forming toxin 
which binds to specific receptors on enterocyte membranes which have been identified to claudins 
leading to loss of fluid and electrolytes [344]. In addition, CPE interacts with nerve endings. Thereby, 
CPE has been found to bind to presynaptic nerve endings in mouse phrenic nerve-diaphragm, possibly 
at synaptophysin sites and to inhibit neurotransmission. CPE seems to block the neuroexocytosis 
process, by a yet unidentified mechanism [345]. The role of CPE interaction with the enteric nervous 
system in the diarrhea development is still unknown. 
The much smaller E. coli heat stable enterotoxins (STa; 2–5 kDa) activate guanylate cyclase, 
increase cyclic guanosine monophosphate (cGMP) levels, and subsequently open Cl
− channels. Since 
STa-induced secretion is blocked by tetrodotoxin, lignocaine, hexamethonium, and also by capsaicin 
and vagotomy, the entero nervous system also likely supports STa activity  [320,346]. The exact 
mechanism of activation of the enteric nervous system by STa is still elusive. VIP antagonist partially 
prevents STa-induced secretion indicating that VIPergic neurons are involved in STa enteric 
activity [347]. However in contrast to cholera toxin, STa seems not to stimulate 5-HT release [330,348]. 
But, STa would activate a NO-dependent myenteric plexus secretory reflex mediated by capsain 
sensitive C fibers [346,348]. VIP and NO seem to have a synergetic effect since NO releases VIP from 
nerve terminals and VIP seems to induce the release of nitric oxide, and both VIP and NO could 
participate in STa enteric activity [330]. STa might also activate neurokinin receptor NK2 to induce 
intestinal secretion [349]. 
4.2.2. Emetic toxins 
4.2.2.1. Bacillus cereus cereulide 
Bacillus cereus is a common foodborne pathogen, which causes two types of gastrointestinal 
diseases in humans, the diarrhoeal and the emetic syndromes. The diarrhoeal disease is due to 
enterotoxins, which are multicomponent toxins produced in situ subsequently to an over proliferation 
of B. cereus in the small intestine, whereas the emesis syndrome results from ingestion of a B. cereus 
emetic toxin, named cereulide, which accumulates in contaminated foods [350].   
Cereulide is a cyclic dodecadepsipeptide (1.2 kDa) which is synthesized by a nonribosomal peptide 
synthetase [351–353]. Cereulide is produced by only certain B. cereus strains which are associated to 
the emetic syndrome [354]. The toxin is stable to acid conditions, proteolysis and heat, and thus it is 
not degraded by gastric acid and digestive proteases. Cereulide is cytotoxic, it induces mitochondria 
swelling (reported first as vacuole formation) in Hep2 cells and necrotic cell death in porcine 
pancreatic Langherans cells, as well as causes emesis in experimental animal models  [355–358]. 
Cytotoxicity towards various primary or cultured cell lines has been reported [359]. The mechanism of 
action of cereulide is only partially known. Cereulide is a K
+ ionophore similarly to valinomycin, as 
evidenced by selective increase in K
+ permeability of phospholipids bilayers induced by the 
toxin [360]. Both toxins are also structurally related [352]. While valinomycin is more potent at high 
K
+ concentration (120 mM), cereulide is more active than valinomycin at low K
+ concentrations  
(1–3 mM) which corresponds to the physiological level in blood serum. Cereulide promotes K
+ uptake 
by mitochondria, efflux of H
+, drop in the transmembrane inner potential, leading to mitochondria Toxins 2010, 2                 
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swelling, arrest of respiratory function, inhibition of ATP synthesis, and release of proapoptotic or 
necrotic factors [360–362]. The emetic effects of cereulide seems to be dependent of stimulation of  
5-HT3 receptors on vagal afferent neurons since 5-HT3 receptor antagonist such as ondanserom 
hydrochloride or vagotony inhibits the emetic effect in suncus [352]. It is not known whether cereulide 
directly interacts with vagal sensory endings or releases 5-HT from enterochromaffin cells. 
4.2.2.2. Staphylococcus enterotoxins 
Staphylococcus aureus produces a myriad of 25–30 kDa, single-chain proteins called the 
staphylococcal enterotoxins (SEs) [363]. These potent toxins cause a prevalent form of food poisoning 
found throughout the world, and these molecules also possess “superantigenic” properties. By classic 
definition, this latter property involves binding to both major histocompatibility complex class II 
(MHC II) on antigen presenting cells and V-specific T-cell receptors, which ultimately cause massive 
T-cell proliferation with a concomitant uncontrolled production/release of various proinflammatory 
cytokines. To date, it is uncertain if superantigenicity plays a direct role in SE-induced food poisoning. 
However, levels of inflammatory mediators like prostaglandins and leukotrienes are increasingly 
evident in the circulatory system of non-human primates shortly after an oral dose of SE type B 
(SEB) [364]. Mast cells may also play a role in SE-induced food poisoning, which perhaps involves 
not only inflammatory mediators, but also stimulation by neuropeptides like substance P released from 
sensory neurons  [365]. Another study reveals that SEB-induced effects in mice (intraperitoneal 
injection) are abrogated by capsaicin, the active ingredient of hot chili peppers, which depletes 
peptidergic sensory nerve fibers and TNF production [366]. An intraperitoneal injection of SEB into 
rats induces expression of Fos (a cell activator) throughout the brain via vagus nerve stimulation, thus 
suggesting that the peripheral presence of an SE has profound effects upon the brain [367]. More 
recently, it has been reported that SE type A (SEA)–induced emesis is mediated by 5-HT. Indeed, 
emesis caused by SEA in animal model (house musk shrew) is inhibited by 5-HT synthesis inhibitor 
and a 5-HT3 receptor antagonist, and in addition SEA increases 5-HT release in the intestine. The 
mechanism of 5-HT release mediated by SEA is not yet known. SEA might interact directly with 
enterochromaffin cells or neurons to trigger 5-HT release, or could act indirectly through the release of 
proinflammatory molecules or free-radical formation  [368]. Mucosal terminals of vagal sensory 
afferent neurons, which project to the emetic center in the brainstem contains 5-HT3 receptors [335]. 
The proposed model includes a SEA-dependent excess release of 5-HT in the intestine and subsequent 
stimulation of 5-HT3 receptors on vagal afferent neurons triggering the emesis (Figure 1) [368]. 
5. Conclusions 
Is neurotoxicity a unique, inherent function of a bacterial toxin? Most bacterial proteins with 
demonstrable “toxic” activity, such as those presented in this review, interact with various cell types. 
For example, more than one third of all bacterial toxins are pore-formers that recognize ubiquitous 
membrane components as receptors, such as cholesterol, gangliosides, and proteins. These toxins can 
indiscriminately damage membranes from different cells, including those of neuronal origin. Among 
them, C. perfringens epsilon toxin has the fundamental structure of a pore-forming toxin, is cytotoxic 
for kidney epithelial cells, and also possesses specific neurotoxic activity. However, a specific Toxins 2010, 2                 
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neurotoxic mechanism of action and trafficking pattern targeting neuronal cells by epsilon toxin during 
the natural course of disease still remains undetermined. Other toxins have developed various 
internalization processes, therefore specifically modifying an intracellular target. Thus, several 
bacterial proteins like the large clostridial toxins (C. sordellii LT and C. difficile ToxA/ToxB) have the 
ability to bind/enter various cell types that include those of neuronal origin. Large clostridial toxins 
inactivate intracellular targets like Rho and/or Ras GTPases, which are involved in multiple signaling 
pathways. Among them, Rac controls the neuroexocytosis process. Thereby, large clostridial toxins 
efficiently block neurotransmitter release, although they do not specifically target neuronal cells. 
Involvement of their neurotoxic activity during disease, which is often overcome by toxic effects upon 
other cell types in natural pathology, is also a function of a toxin’s opportunity to enter neuronal cells 
near the infection site. Various bacterial enterotoxins, which have developed a specific mode of 
interaction with enterocytes, amplify their intestinal activity by stimulating the secretomotor reflex 
from the enteric nervous system, like CT, or interact with distinct nervous afferences on the intestinal 
mucosa leading to vomiting. It is noteworthy that the enteric nervous system is a preferential target for 
many bacterial toxins, which transit through the intestinal tract. Finally, two unique classes of 
neurotoxins, BoNTs and TeNT, have evolved as specific inhibitors of the neuroexocytosis machinery. 
These bacterial proteins recognize specific receptors on neuronal cells and only interfere intracellularly 
with highly specialized molecules, like the SNARE proteins, which play a pivotal role in evoked 
release of neurotransmitter. It is intriguing that toxins produced by environmental bacteria, which are 
not normally adapted for a commensal life with higher organisms and only interact accidentally with 
them, possess such specific and highly sophisticated tools. What is the underlying selective pressure 
for such evolution from a bacterial protease to a neurotoxin? Perhaps neurotoxins simply result from 
an evolutionary process independent of the host. What is the inherited benefit derived by an 
environmental bacterium to produce a neurotoxin, which apparently does not recognize other bacterial 
or environmental substrates? Clearly, we approach this from a scientist’s (human) perspective, and 
with such an inherent bias that it may be difficult and virtually impossible to truly understand this 
natural curiosity. During their evolution, clostridial pathogens have developed a potent arsenal of 
noxious proteins that affect the central and peripheral nervous system of various vertebrates. These 
commonly named neurotoxins specifically target some key functions, or cellular processes, of 
eukaryotic cells, which subsequently cause a wide array of life-threatening diseases in humans and 
animals. These neurotoxins bind to specific receptors in the plasma membrane of susceptible host cells 
and translocate their enzymatically active domains/subunits into the cytosol, where finally they elicit 
the deleterious effects commonly associated with the holotoxins. Modes of action for the neurotoxic 
proteins reviewed here have been deciphered during the last decade, and now a clearer picture of their 
intracellular substrates is emerging. The specificity of these toxic proteins has enabled them to become 
useful tools to elucidate and characterize crucial processes for eukaryotic cells, which include 
neurotransmitter release, physiological signaling pathways, and constitutive cellular mechanisms. 
However, additional studies are needed to completely identify their specific membrane-receptors, as 
well as comprehend the mechanisms and structures involved in toxin routing throughout the nervous 
system. Thus, multidisciplinary approaches integrating molecular microbiology, membrane biology, 
biochemistry, physiology, proteomics, and pharmacology will further advance our understanding of 
the transport mechanisms required for directing molecules to specific locations within the nervous Toxins 2010, 2                 
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system of eukaryotes. Clearly, specificity of action for the BoNTs has made them very useful 
therapeutic agents for many human neurological syndromes caused by hyperactivity of cholinergic 
nerve terminals. It is expected that future pharmacological developments will employ the inherent 
capabilities of various toxins to deliver biologically-active substances into nerve cells. 
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